<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860856</url>
  </required_header>
  <id_info>
    <org_study_id>OS19011 IRB 2019-0366</org_study_id>
    <nct_id>NCT04860856</nct_id>
  </id_info>
  <brief_title>Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial</brief_title>
  <official_title>Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of an intra-operative, post-fixation&#xD;
      fracture hematoma block compared to saline control on postoperative pain control in patients&#xD;
      with acute femoral shaft fractures. Our primary outcome measure is visual analog scale (VAS)&#xD;
      pain scores which are recorded at regular intervals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This blinded, randomized control trial is being performed at the University of Cincinnati&#xD;
      Medical Center.&#xD;
&#xD;
      Patients will be randomly assigned to one of two treatment groups: Group One will be&#xD;
      comprised of patients treated with fracture site injection containing 20 mL of 0.5%&#xD;
      ropivacaine with an 18-gauge needle (150 mm length), Group Two will be comprised of patients&#xD;
      treated with fracture site injection containing 20ml of normal saline. The injection will be&#xD;
      administered by the orthopaedic trauma team after the insertion of the final intramedullary&#xD;
      implant and skin closure prior to final surgical dressing application. The injection will be&#xD;
      performed in a standard fashion with aspiration of hematoma followed by the injection. All&#xD;
      postoperative management will be per standard of care.&#xD;
&#xD;
      The size of the hematoma will have no effect on the procedure. When a hematoma block is&#xD;
      utilized in the care of orthopaedic trauma patients, its aim is to infiltrate the anesthetic&#xD;
      to the fracture edges and injured soft tissue to allow for pain control and fracture&#xD;
      manipulation without additional sedation. Aspiration of the hematoma tells the clinician that&#xD;
      the tip of the needle is near the fracture site and not in a neurovascular structure.&#xD;
&#xD;
      The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5%&#xD;
      ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine.&#xD;
      100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient&#xD;
      weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.&#xD;
&#xD;
      Regional anesthesia including nerve blocks is not routinely used in the setting of traumatic&#xD;
      femoral shaft fractures. A nerve block would compromise the patient's neurologic examination&#xD;
      in the immediate postoperative period.&#xD;
&#xD;
      Randomization will be performed via Microsoft Excel to generate random numbers. Allocation&#xD;
      will be concealed and revealed to the surgical team in the hour prior to the procedure. The&#xD;
      patients and the nursing staff who assess postoperative pain will be blinded to the treatment&#xD;
      allocation.&#xD;
&#xD;
      An a priori power analysis was performed to determine the sample size for the primary outcome&#xD;
      measure. Prior literature has indicated that a difference of 1.3 on a VAS is clinically&#xD;
      significant.5 Therefore, it was determined that a total of 44 patients were necessary per&#xD;
      group to detect a 1.5-point difference on the VAS (power = 80%, p = 0.05).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Blinded, randomized control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The patients and the nursing staff who assess postoperative pain will be blinded to the treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postoperative pain at 72 hours</measure>
    <time_frame>Measured at 0, 8, 16, 24, 36, 48, and 72 hours postoperatively</time_frame>
    <description>Postoperative pain will be assessed using a visual analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic usage</measure>
    <time_frame>Narcotic usage will be assessed through 72 hours postoperatively</time_frame>
    <description>Oral morphine equivalents will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Femur Fracture</condition>
  <arm_group>
    <arm_group_label>Hematoma block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fracture site injection of 20 mL of 0.5% ropivacaine with an 18-gauge needle (150 mm length).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fracture site injection of 20ml of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% ropivacaine</intervention_name>
    <description>The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.</description>
    <arm_group_label>Hematoma block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>20ml of normal saline</description>
    <arm_group_label>Normal saline injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Trauma patient at the University of Cincinnati Medical Center&#xD;
&#xD;
          -  Skeletally mature patients&#xD;
&#xD;
          -  Have an isolated, closed, acute traumatic femoral shaft fracture to be treated with a&#xD;
             closed reduction and reamed intramedullary rod fixation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Member of a vulnerable patient population&#xD;
&#xD;
          -  Have additional injuries&#xD;
&#xD;
          -  Have a history of prior existing narcotic use or chronic pain management issues on&#xD;
             presentation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>He C S, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly A Hasselfeld</last_name>
    <phone>5137776213</phone>
    <email>hasselky@uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cincinnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Hasselfeld</last_name>
      <phone>513-777-6213</phone>
      <email>hasselky@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Henry C Sagi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alioto RJ, Furia JP, Marquardt JD. Hematoma block for ankle fractures: a safe and efficacious technique for manipulations. J Orthop Trauma. 1995 Apr;9(2):113-6.</citation>
    <PMID>7776029</PMID>
  </reference>
  <reference>
    <citation>Bear DM, Friel NA, Lupo CL, Pitetti R, Ward WT. Hematoma block versus sedation for the reduction of distal radius fractures in children. J Hand Surg Am. 2015 Jan;40(1):57-61. doi: 10.1016/j.jhsa.2014.08.039. Epub 2014 Oct 11.</citation>
    <PMID>25306504</PMID>
  </reference>
  <reference>
    <citation>Case RD. Haematoma block--a safe method of reducing Colles' fractures. Injury. 1985 Jul;16(7):469-70.</citation>
    <PMID>4030071</PMID>
  </reference>
  <reference>
    <citation>Herrera JA, Wall EJ, Foad SL. Hematoma block reduces narcotic pain medication after femoral elastic nailing in children. J Pediatr Orthop. 2004 May-Jun;24(3):254-6.</citation>
    <PMID>15105718</PMID>
  </reference>
  <reference>
    <citation>Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med. 2001 Dec;38(6):633-8.</citation>
    <PMID>11719741</PMID>
  </reference>
  <reference>
    <citation>Koehler D, Marsh JL, Karam M, Fruehling C, Willey M. Efficacy of Surgical-Site, Multimodal Drug Injection Following Operative Management of Femoral Fractures: A Randomized Controlled Trial. J Bone Joint Surg Am. 2017 Mar 15;99(6):512-519. doi: 10.2106/JBJS.16.00733.</citation>
    <PMID>28291185</PMID>
  </reference>
  <reference>
    <citation>Johnson PQ, Noffsinger MA. Hematoma block of distal forearm fractures. Is it safe? Orthop Rev. 1991 Nov;20(11):977-9.</citation>
    <PMID>1749663</PMID>
  </reference>
  <reference>
    <citation>Dimopoulou I, Anagnostou TL, Prassinos NN, Savvas I, Patsikas M. Effect of intrafragmentary bupivacaine (haematoma block) on analgesic requirements in dogs undergoing fracture repair. Vet Anaesth Analg. 2017 Sep;44(5):1189-1197. doi: 10.1016/j.vaa.2017.01.005. Epub 2017 Mar 6.</citation>
    <PMID>29100681</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Ruixian Yue</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Femoral Intramedullary Rod</keyword>
  <keyword>Hematoma Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

